Subscribe
istock-629794242xesai-1
Xesai / iStockphoto.com
2 August 2018Americas

Patent abuse driving high drug prices, non-profit claims

Aggressive and exploitative patenting strategies are enabling drug makers to regularly increase prices in the US and extend monopolies, according to a new report from non-profit group the Initiative for Medicines, Access and Knowledge (I-MAK).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
‘Pervasive abuse’ of patent system at root of drug pricing crisis: I-MAK
20 September 2022   Report found that four times as many patents are granted on the top ten drugs in the US, compared to Europe | Non-profit says that the US’ patent system is ‘broken’.
Americas
PTAB shoots down tenth I-MAK Gilead challenge
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.


Editor's picks

Why US patent reform is ‘essential’ for US economic prosperity and security
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

Editor's picks

Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025

More on this story

Americas
‘Pervasive abuse’ of patent system at root of drug pricing crisis: I-MAK
20 September 2022   Report found that four times as many patents are granted on the top ten drugs in the US, compared to Europe | Non-profit says that the US’ patent system is ‘broken’.
Americas
PTAB shoots down tenth I-MAK Gilead challenge
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

More on this story

Americas
‘Pervasive abuse’ of patent system at root of drug pricing crisis: I-MAK
20 September 2022   Report found that four times as many patents are granted on the top ten drugs in the US, compared to Europe | Non-profit says that the US’ patent system is ‘broken’.
Americas
PTAB shoots down tenth I-MAK Gilead challenge
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

More features

US warns of rising counterfeit drug threat from India and China
Judge denies Pfizer and BioNTech bid to see off COVID-19 vaccine suit
Biotech and healthcare expert returns to Latham & Watkins
AstraZeneca to appeal invalidated diabetes patent in generics dispute
Why US patent reform is ‘essential’ for US economic prosperity and security
Medical company sees $452m trade secrets award cut by 87%
Fed Circ: Generic doesn’t infringe Metacel MS drug
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025